vx-765
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00205465)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Caspase-1INHIBITOR
CASP1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C- Mol. weight
- 509 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2107819 ↗
Also known as
- 1-(2-((1-(4-amino-3-chlorophenyl)methanoyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylic acid
- vx 765
- vx-765
- vx-765
- vx-765
- vx-765
- vx765 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05164120 | Phase 2 | Dec 14, 2021 | Georgetown University |
| NCT01501383 | Phase 2 | Dec 1, 2011 | Vertex |
| NCT01048255 | Phase 2 | Jan 1, 2010 | Vertex |
| NCT00205465 | Phase 2 | Dec 1, 2004 | Vertex |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 3 | 3 | 1 | 2004 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1